NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Hongene Biotechnology

Hongene Biotechnology

Private
ShanghaiHealthcare & Life Scienceshttps://www.hongene.com/

Last Round

Grant

Oct 1, 2025

Total Funding Raised

$1.23M

Company Overview

Hongene Biotechnology is a biotechnology company that provides nucleic acid raw materials and contract development and manufacturing organization (CDMO) services for the pharmaceutical and biotech industries.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Pharma Supply Chain, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Non-AI

Keywords

contract development and manufacturing organizationCDMOnucleic acid therapeuticsoligonucleotide synthesisphosphoramiditesmRNA raw materialsGMP manufacturingcustom synthesisbiotech supply chainRNA synthesisDNA synthesisbiopharma manufacturingcapping analogsmodified nucleotidesbiotech outsourcing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hongene Biotechnology Comparables

Compare Hongene Biotechnology with similar companies based on industry and business-model similarity.

Hongene Biotechnology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BioSpring GmbH
85%
Innovassynth Technologies (India) Ltd
84%
ST Pharm Co.,Ltd
80%

Hongene Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 1, 2025
Private EquityMay 24, 2020

Hongene Biotechnology Investors

Notable investors and investment history

Hongene Biotechnology investors
InvestorRounds
HighLight CapitalPrivate Equity
中信金石投资有限公司Private Equity
Huasheng CapitalPrivate Equity
Bill & Melinda Gates FoundationGrant
Addor CapitalPrivate Equity
CITIC Securities InvestmentPrivate Equity
HongShan Capital Group (HSG)Private Equity

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 5, 2025

    Dr. Pieter Cullis joins the scientific advisory board.

  • May 3, 2025

    Monthly visitors increased 40% MoM to 9.8K.

Hongene Biotechnology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hongene Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hongene Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range70
Year Founded1998
Last FundingOct 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.